Brief: Genflow Biosciences To Start Preliminary Talks With EMA On ODA For GF-3001
01/02/2024 07:50
Feb 1 (Reuters) - Genflow Biosciences PLC GENF.L :
* GENFLOW BIOSCIENCES: TO UNDERTAKE KEY IND-ENABLING
DEVELOPMENT
ACTIVITIES IN 2024 TO HELP DEFINE PHARMACOLOGICAL &
TOXICOLOGICAL PROPERTIES OF GF-1002
* GENFLOW BIOSCIENCES: IN 2024 PLANS TO COMMENCE PRELIMINARY
DISCUSSIONS WITH EMA ON MOA DATA FOR ODA FOR GF-3001, TARGETING
WERNER SYNDROME
Source text for Eikon: ID:nRSA4088Ba
Further company coverage: GENF.L
((Reuters.Briefs@thomsonreuters.com;))